LENVATINIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion.
Embrace-III Hi-Risk
Phase 2 small_molecule active
Quick answer
LENVATINIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion. for high risk or poor response after chemoradiation and brachytherapy for locally advanced cervix cancer is a Phase 2 program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Disc Medicine
- Indication
- high risk or poor response after chemoradiation and brachytherapy for locally advanced cervix cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active